{"name":"Omeros","slug":"omeros","ticker":"OMER","exchange":"NASDAQ","domain":"omeros.com","description":"Omeros is an epic poem by Saint Lucian writer Derek Walcott, first published in 1990. The work is divided into seven \"books\" containing a total of sixty-four chapters. Many critics view Omeros as Walcott's finest work.","hq":"Seattle, WA","founded":0,"employees":"","ceo":"Gregory Demopulos","sector":"Ophthalmology / Complement","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$380M","metrics":{"revenue":160000000,"revenueGrowth":35.7,"grossMargin":0,"rdSpend":119523000,"netIncome":-156815000,"cash":277079000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2025-01-01","label":"Yartemlea first approved","drug":"Yartemlea","drugSlug":"narsoplimab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"OMIDRIA patent cliff ($100M at risk)","drug":"OMIDRIA","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Yartemlea","genericName":"NARSOPLIMAB","slug":"narsoplimab","indication":"hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"YARTEMLEA","genericName":"NARSOPLIMAB-WUUG","slug":"narsoplimab-wuug","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Yartemlea","genericName":"NARSOPLIMAB","slug":"narsoplimab","phase":"marketed","mechanism":"Narsoplimab works by targeting and modulating the immune system to prevent damage to blood vessels.","indications":["hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)"],"catalyst":""},{"name":"YARTEMLEA","genericName":"NARSOPLIMAB-WUUG","slug":"narsoplimab-wuug","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Omeros Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Omeros reported fourth quarter and full year 2023 financial results, with net loss of $13.4 million and $55.6 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Omeros Announces Collaboration with Biogen to Develop Complement Inhibitors","summary":"Omeros announced a collaboration with Biogen to develop complement inhibitors for the treatment of neurodegenerative diseases.","drugName":"","sentiment":"positive"},{"date":"2023-08-14","type":"regulatory","headline":"FDA Approves OMIDRIA for Use During Cataract Surgery","summary":"The FDA approved OMIDRIA for use during cataract surgery, expanding its indication to include use in patients undergoing cataract surgery.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOWFp0RVJoZ1ZETjZmVFF0R3ZMX001ZklKNFpIOVBYbEhXaUtKeVp3Z1ZVRC0wWnFHbVpteERCdmhnck1TRXVncXFrTm8tNjl4Z1otUkF6S1dfRHh2YzdPM0t6Z1d0X2pPTkpualptUV9Qd2M0SmZJZ2VDckJ6Vnl4WFh0eW1oYjE1WEhnd0QzbXhjc0NwVE1PVjVB?oc=5","date":"2026-01-08","type":"regulatory","source":"TechStock²","summary":"Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set - TechStock²","headline":"Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set - TechStock²","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-05","type":"regulatory","source":"simplywall.st","summary":"Assessing Omeros (OMER) Valuation After YARTEMLEA’s FDA Approval And Planned US Launch - simplywall.st","headline":"Assessing Omeros (OMER) Valuation After YARTEMLEA’s FDA Approval And Planned US Launch","sentiment":"positive"},{"date":"2025-12-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPaVlCY2RiNUYzTHItSVAtV3dvLU9fdDNsSW5UTEVHTURNMEVvT0d0M2U3NGFBeXFzaERCT05HbC1WemJKTVAyLVRYUTg1cDRMZXQyTjRqZjV1TFF2RUZ6MG1WMmFBZjI1cnhNSlI3Zm1FbHUwTTlIMVYzV3NPM3lpN0NZYUZ3ZVV2ZXBRMm5adFRrWDI2b243bloxdXhzN0NqSHFRNHZpb0pDT1A2cFZOWXN1N29VOTExUmJoYklHRkhycGdoMnQtd2o5Y3U4QVUweDR3V0Jn?oc=5","date":"2025-12-24","type":"regulatory","source":"Reuters","summary":"US FDA approves Omeros' drug to treat dangerous transplant complication - Reuters","headline":"US FDA approves Omeros' drug to treat dangerous transplant complication","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNUUpUUXhyRTdKZkRRQVY2LVN6NzdzTFE1WU04VW1GU2lXN3VrRzlyWmFPRGhFNE1VX3dQbmRwS3VQd09pY3RZRVVkVVphbDl1dHpwYkJhQnBDQk9LQjZKbl9udnFITmJPdHhfNjNWMlFyOEEwLVA3WUZfSmhxZkpyMkFsOA?oc=5","date":"2025-12-24","type":"pipeline","source":"The Motley Fool","summary":"Why Omeros Stock Skyrocketed Today - The Motley Fool","headline":"Why Omeros Stock Skyrocketed Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOOE1nTmhramdnUms1VWRoemxSWTdwNmhCXzUtRUtFNXl1RGFXMFJ4WWZUeFNxcXJoYWdKMjVVOVNHV25nWURrZ1RFem9DekNlVjNtN2RNTmoyYmZjd2pSMzEtU2Radk5KOFdKQmhKNWtpWHR5NWkwNGRJRU1xblFSTUdLNDlqYTlFaTM4RWt0MFkzcERMcm5qS0ZlYTlFaFoyS1ltOG1GRjcyLTNxcnk2QUdEVGJWZGN2Y3ZrTG5HUkYxYWZ3aTI1dHNEUWZJUHlHdUdoX0pSSTdoQQ?oc=5","date":"2025-12-24","type":"regulatory","source":"TechStock²","summary":"Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open - TechStock²","headline":"Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Mark","sentiment":"positive"},{"date":"2025-12-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-29","type":"pipeline","source":"simplywall.st","summary":"Omeros Corporation (NASDAQ:OMER): When Will It Breakeven? - simplywall.st","headline":"Omeros Corporation (NASDAQ:OMER): When Will It Breakeven?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxPWGtSak13bFFkVmpKTUJWRjVUNjVYMVRaVzdTbHV6NGk0WnpadjFCRFdVSGwyRG1EWlkyNGJ2RU9idExmVExOWE52YVBrd3FoRXFEUkNVN2ZEWEFNelNNWE9hMkhfR3hwVHZ6dXZsczVEXzZPRzlNbTZvTUk0Q2ljWDluWExSRVV2YjlyZENZaXNFRDZMQV9pSU1hT3BDVGViNWw4M3ladFFfV29lWlVtbmliRW83WkJ3dEFleGRJRGlkU1NOSUN0MU9SWHREZXJQZ3lRNHI0cWIyQlk2OF9ZbjgtRk13T3RvV1RuUzY0enhWaGRBUkE?oc=5","date":"2025-11-14","type":"pipeline","source":"Benzinga","summary":"Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday - Benzinga","headline":"Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBTVEVaQWZoa0VDRzhCbEMtQ1dlQmFDM0h4TUdJWkNkT2g5TGtDSHg0WUJCQm9lWko2cE1LOTl5VEJpMVVldWxUdWNKT2NjTTBwYmE1MlJRWE5pYW5halIwWnBXdHdyckdzeXJtOEdJTURzR3prZ2QzaW5XZTlsU2M?oc=5","date":"2025-10-15","type":"deal","source":"Yahoo Finance","summary":"Novo Nordisk Just Signed a Key Drug Deal With Omeros. Is There Any Room Left for OMER Stock to Run? - Yahoo Finance","headline":"Novo Nordisk Just Signed a Key Drug Deal With Omeros. Is There Any Room Left for OMER Stock to Run?","sentiment":"neutral"}],"patents":[{"drugName":"OMIDRIA","drugSlug":"phenylephrine-and-ketorolac","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alcon","Bausch Health","Regeneron"],"therapeuticFocus":["Ophthalmology","Complement"],"financials":{"source":"sec_edgar+yahoo","revenue":29868000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":29868000,"period":"2018-12-31"},{"value":22017000,"period":"2018-12-31"},{"value":4608000,"period":"2018-09-30"},{"value":1655000,"period":"2018-06-30"},{"value":1588000,"period":"2018-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":119523000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-156815000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":277079000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}